The company's joint venture Aleor Dermaceuticals has got USFDA approval for a spray to treat plaque psoriasis.
Shares of Alembic Pharmaceuticals rose 3 percent intraday on October 4 after the company's joint venture received the USFDA’s approval for a spray used for treating plaque psoriasis.
Aleor Dermaceuticals (Aleor) has got the US Food and Drug Administration nod to for its abbreviated new drug application (ANDA) Clobetasol Propionate Spray, 0.05%.
ANDA is a therapeutically equivalent to the reference listed drug product, Clobex Spray, 0.05%, of Galderma Laboratories LP.
Clobetasol Propionate Spray is used in the treatment of moderate to severe plaque psoriasis affecting up to 20 percent body surface area.
It had an estimated market size of $22 million for twelve months ending December 2018, according to IQVIA.At 1109 hours, Alembic Pharmaceuticals was quoting at Rs 535, up Rs 9.45, or 1.80 percent, on the BSE.Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.